细胞周期进展评分在非裔美国与非裔美国局限性前列腺癌患者中的预后效用比较
该回顾性队列研究纳入2006至2011年在Ochsner诊所诊断的767例局限性前列腺癌患者(36.6%为非裔美国人),评估细胞周期进展(CCP)评分和临床细胞周期风险(CCR)评分对转移的预测价值。多变量分析显示CCP评分(HR 2.04,p<0.001)和CCR评分(HR 3.86,p<0.001)均为转移的显著预测因子,且与 ancestry 或治疗无交互作用。结论认为CCR评分提供独立于 ancestry 的预后信息,非裔美国患者预后相似。
要点
- CCP评分是转移的独立预测因子(HR 2.04,p<0.001),与 ancestry 无交互(p=0.20)。
- CCR评分预后价值更高(HR 3.86,p<0.001),与 ancestry 无交互(p=0.24)。
- 校正分子和临床病理变量后,非裔美国与非裔美国患者前列腺癌结局相似。
核心结论
- CCR评分提供显著的预后信息,且不依赖于 ancestry。
- 校正所有可用分子和临床病理变量后,非裔美国患者前列腺癌结局与非裔美国患者相似。
研究设计与样本
- CCP评分从档案福尔马林固定石蜡包埋活检组织得出,CCR评分结合CCP评分与CAPRA评分。
主要发现
- 多变量分析校正 ancestry、治疗和CAPRA后,CCP评分仍显著预测转移(HR 2.04;p<0.001),与 ancestry 无交互(p=0.20),与治疗无交互(p=0.09)。
- CCR评分高度预后(HR 3.86;p<0.001),与 ancestry 无交互(p=0.24),与治疗无交互(p=0.32)。
临床怎么用
- CCR评分可用于新诊断前列腺癌患者的转移风险评估,不受 ancestry 或治疗方式影响,辅助治疗决策。
- 在非裔美国患者中,CCR评分同样提供预后信息,支持其在该人群中的应用。
局限性
- 回顾性研究设计。
- 使用自我报告的 ancestry 信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Better prostate cancer risk stratification is necessary to inform medical management, especially for African American (AA) men, for whom outcomes are particularly uncertain. OBJECTIVE: To evaluate the utility of both a cell cycle progression (CCP) score and a clinical cell-cycle risk (CCR) score to predict clinical outcomes in a large cohort of men with prostate cancer highly enriched in an AA patient population. DESIGN, SETTING, AND PARTICIPANTS: Patients were diagnosed with clinically localized adenocarcinoma of the prostate and treated at The Ochsner Clinic (New Orleans, LA, USA) from January 2006 to December 2011. CCP scores were derived from archival formalin-fixed, paraffin-embedded biopsy tissue. CCR scores were calculated as the combination of molecular (CCP score) and clinical (Cancer of the Prostate Risk Assessment [CAPRA] score) components. INTERVENTION: Active treatment (radical prostatectomy, radiation therapy alone, or radiation and hormone therapy) or watchful waiting. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcome was progression to metastatic disease. Association with outcomes was evaluated via Cox proportional hazards survival analysis and likelihood ratio tests. RESULTS AND LIMITATIONS: The final cohort included 767 men, of whom 281 (36.6%) were AA. After accounting for ancestry, treatment, and CAPRA in multivariable analysis, the CCP score remained a significant predictor of metastatic disease (hazard ratio [HR] 2.04; p<0.001), and there was no interaction with ancestry (p=0.20) or treatment (p=0.09). The CCR score was highly prognostic (HR 3.86; p<0.001), and as with the CCP score, there was no interaction with ancestry (p=0.24) or treatment (p=0.32). Limitations include the retrospective study design and the use of self-reported ancestry information. CONCLUSIONS: A CCR score provided significant prognostic information regardless of ancestry. The findings demonstrate that AA men in this study cohort appear to have similar prostate cancer outcomes to non-AA patients after accounting for all available molecular and clinicopathologic variables. PATIENT SUMMARY: In this study we evaluated the ability of a combined molecular and clinical score to predict the progression of localized prostate cancer. We found that the combined molecular and clinical score predicted progression to metastasis regardless of patient ancestry or treatment. This suggests that the combined molecular and clinical score may be a valuable tool for determining the risk of metastasis in men with newly diagnosed prostate cancer in order to make appropriate treatment decisions.
引用
- Canter DJ, Reid J, Latsis M, et al. Comparison of the Prognostic Utility of the Cell Cycle Progression Score for Predicting Clinical Outcomes in African American and Non-African American Men with Localized Prostate Cancer. Eur Urol. 2018. PMID: 30391079. doi:10.1016/j.eururo.2018.10.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。